{
    "organizations": [],
    "uuid": "bc12919b0ac4abb0b0a68055191567029acd588a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-onxeo-fy-recurring-operating-loss/brief-onxeo-fy-recurring-operating-loss-narrows-to-eur-19-2-million-idUSW8N1KI00J",
    "ord_in_thread": 0,
    "title": "Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - ONXEO SA:\n* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO\n* FY RECURRING OPERATING LOSS EUR 19.2‍​ MILLION VERSUS LOSS OF EUR 23.2 MILLION YEAR AGO\n* FY NET LOSS EUR 59.1‍​ MILLION VERSUS LOSS OF EUR 22.7 MILLION YEAR AGO\n* END-DEC. CASH POSITION OF EUR 14.3 MILLION, COVERING CURRENT PROGRAMME UNTIL MID-2019\n* LAUNCH OF PRECLINICAL STUDIES WITH FIRST MOLECULE GENERATED BY PLATON EXPECTED BEFORE END-2018\n* RESULTS OF STUDY ON COMBINATION OF BELINOSTAT AND ASIDNA TO BE PRESENTED AT 2018 AACR CONGRESS\n* RESULTS OF SECOND PHASE I CLINICAL STUDY WITH ASIDNA, DRIIV, EXPECTED BEFORE YEAR-END\n* SAYS MIGHT BE ABLE TO LAUNCH CLINICAL TRIAL WITH BELINOSTAT AND ASIDNA COMBINATION IN 2018 Source text: bit.ly/2GWPAfS Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-30T00:33:00.000+03:00",
    "crawled": "2018-03-30T12:45:57.049+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "onxeo",
        "sa",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "recurring",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "cash",
        "position",
        "eur",
        "million",
        "covering",
        "current",
        "programme",
        "launch",
        "preclinical",
        "study",
        "first",
        "molecule",
        "generated",
        "platon",
        "expected",
        "result",
        "study",
        "combination",
        "belinostat",
        "asidna",
        "presented",
        "aacr",
        "congress",
        "result",
        "second",
        "phase",
        "clinical",
        "study",
        "asidna",
        "driiv",
        "expected",
        "say",
        "might",
        "able",
        "launch",
        "clinical",
        "trial",
        "belinostat",
        "asidna",
        "combination",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}